Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Innovative Biosensors was a Maryland-based biotechnology company that specialized in the development of rapid pathogen detection systems for biodefense, food safety, and clinical diagnostics. The company's core technology, CANARY (Cellular Analysis and Notification of Antigen Risks and Yields), utilized genetically engineered B-cells to identify bacteria, viruses, and toxins with high sensitivity and speed. Their primary product lines included the BioFlash air sampler, designed for real-time biothreat monitoring, and the Zephyr system, which focused on foodborne pathogen testing. Founded in 2003, the company successfully commercialized its biosensor platforms before its assets were acquired by PathSensors in 2010. The technology remains a significant benchmark in the field of rapid, cell-based diagnostic sensing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Innovative Biosensors.